Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Given Consensus Recommendation of “Reduce” by Analysts

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) has been assigned an average rating of “Reduce” from the ten brokerages that are presently covering the firm, Marketbeat reports. Four research analysts have rated the stock with a sell rating and six have given a hold rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $28.00.

Several research analysts recently issued reports on FMS shares. Truist Financial set a $28.00 target price on shares of Fresenius Medical Care AG & Co. KGaA in a report on Monday, January 5th. Wall Street Zen cut shares of Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “buy” rating in a report on Sunday, April 26th. The Goldman Sachs Group cut shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a report on Tuesday, January 20th. Jefferies Financial Group cut shares of Fresenius Medical Care AG & Co. KGaA from a “moderate sell” rating to a “strong sell” rating in a report on Tuesday, February 24th. Finally, Erste Group Bank cut shares of Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 5th.

Fresenius Medical Care AG & Co. KGaA Trading Up 0.0%

NYSE FMS opened at $22.50 on Monday. The company has a fifty day simple moving average of $22.86 and a two-hundred day simple moving average of $23.56. The stock has a market cap of $12.57 billion, a P/E ratio of 11.78, a P/E/G ratio of 2.74 and a beta of 0.81. Fresenius Medical Care AG & Co. KGaA has a 12-month low of $20.94 and a 12-month high of $30.46. The company has a current ratio of 1.26, a quick ratio of 0.92 and a debt-to-equity ratio of 0.40.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last posted its quarterly earnings results on Saturday, February 14th. The company reported $1.69 earnings per share (EPS) for the quarter. The business had revenue of $5.95 billion during the quarter. Fresenius Medical Care AG & Co. KGaA had a net margin of 5.03% and a return on equity of 8.73%. On average, analysts forecast that Fresenius Medical Care AG & Co. KGaA will post 2.45 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. Sequoia Financial Advisors LLC purchased a new position in shares of Fresenius Medical Care AG & Co. KGaA during the first quarter worth $457,000. DMC Group LLC raised its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 15.3% during the first quarter. DMC Group LLC now owns 22,460 shares of the company’s stock worth $507,000 after purchasing an additional 2,986 shares during the last quarter. Kathmere Capital Management LLC purchased a new position in shares of Fresenius Medical Care AG & Co. KGaA during the first quarter worth $219,000. QRG Capital Management Inc. grew its position in Fresenius Medical Care AG & Co. KGaA by 13.8% during the first quarter. QRG Capital Management Inc. now owns 77,128 shares of the company’s stock valued at $1,740,000 after buying an additional 9,357 shares during the period. Finally, Moran Wealth Management LLC grew its position in Fresenius Medical Care AG & Co. KGaA by 31.5% during the first quarter. Moran Wealth Management LLC now owns 347,773 shares of the company’s stock valued at $7,846,000 after buying an additional 83,311 shares during the period. Hedge funds and other institutional investors own 8.37% of the company’s stock.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.